CONCORD BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,452 INR | -0.52% |
|
+1.39% | -1.37% |
| 05-23 | Concord Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| 05-23 | Concord Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 151,866 | - | - |
| Enterprise Value (EV) 1 | 159,100 | 150,228 | 148,823 |
| P/E ratio | 51.6 x | 39.4 x | 30.4 x |
| Yield | 0.43% | 0.53% | 0.67% |
| Capitalization / Revenue | 15.6 x | 12.3 x | 10 x |
| EV / Revenue | 15.6 x | 12.2 x | 9.84 x |
| EV / EBITDA | 36.9 x | 28.1 x | 22.1 x |
| EV / FCF | 166 x | 56 x | 45.9 x |
| FCF Yield | 0.6% | 1.79% | 2.18% |
| Price to Book | 9.92 x | 8.28 x | 6.81 x |
| Nbr of stocks (in thousands) | 104,616 | - | - |
| Reference price 2 | 1,452 | 1,452 | 1,452 |
| Announcement Date | 24/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 10,169 | 12,327 | 15,129 |
| EBITDA 1 | - | 4,316 | 5,348 | 6,731 |
| EBIT 1 | - | 3,780 | 4,799 | 6,137 |
| Operating Margin | - | 37.17% | 38.93% | 40.56% |
| Earnings before Tax (EBT) 1 | - | 4,126 | 5,091 | 6,602 |
| Net income 1 | 2,401 | 3,081 | 3,871 | 4,988 |
| Net margin | - | 30.3% | 31.4% | 32.97% |
| EPS 2 | 22.95 | 29.45 | 36.88 | 47.82 |
| Free Cash Flow 1 | - | 911.5 | 2,684 | 3,245 |
| FCF margin | - | 9.19% | 21.78% | 21.45% |
| FCF Conversion (EBITDA) | - | 21.56% | 50.19% | 48.21% |
| FCF Conversion (Net income) | - | 30.29% | 69.34% | 65.06% |
| Dividend per Share 2 | - | 6.280 | 7.755 | 9.705 |
| Announcement Date | 01/07/23 | 24/05/24 | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 630 | 1,638 | 3,043 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | 912 | 2,684 | 3,245 |
| ROE (net income / shareholders' equity) | - | 21.4% | 22.5% | 24.2% |
| ROA (Net income/ Total Assets) | - | 19% | 19% | 21% |
| Assets 1 | - | 15,837 | 20,374 | 23,752 |
| Book Value Per Share 2 | - | 146.0 | 175.0 | 213.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 1,433 | 550 | 600 |
| Capex / Sales | - | 14.45% | 4.46% | 3.97% |
| Announcement Date | 01/07/23 | 24/05/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,452
INR
Average target price
1,597
INR
Spread / Average Target
+10.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.37% | 1.83B | |
| -2.00% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.86% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +4.94% | 8.94B |
- Stock Market
- Equities
- CONCORDBIO Stock
- Financials Concord Biotech Limited
